Profile data is unavailable for this security.
About the company
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
- Revenue in AUD (TTM)84.68m
- Net income in AUD1.59m
- Incorporated1998
- Employees237.00
- LocationPolynovo Ltd2/320 Lorimer StreetMELBOURNE 3207AustraliaAUS
- Phone+61 80095-8289
- Fax+61 38681-4099
- Websitehttps://polynovo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dimerix Ltd | 181.28k | -10.87m | 354.56m | 0.00 | -- | 160.10 | -- | 1,955.88 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 395.60m | 900.00 | -- | 0.6897 | -- | 1.42 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Imugene Ltd | 0.00 | -89.24m | 424.55m | 0.00 | -- | 2.13 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 489.94m | 23.00 | -- | 13.11 | -- | 22.74 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 519.80m | 1.00 | -- | 11.25 | -- | 2,594.05 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Immutep Ltd | 256.62k | -40.50m | 614.53m | 19.00 | -- | 4.25 | -- | 2,394.70 | -0.039 | -0.039 | 0.0002 | 0.0964 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 741.54m | 16.00 | 25.41 | 4.15 | 23.81 | 8.50 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Mesoblast Ltd | 11.25m | -110.11m | 1.23bn | 83.00 | -- | 1.43 | -- | 109.59 | -0.1335 | -0.1335 | 0.0137 | 0.7556 | 0.0112 | -- | 3.71 | 135,571.80 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| Polynovo Ltd | 84.68m | 1.59m | 1.62bn | 237.00 | 1,017.39 | 23.39 | 410.09 | 19.07 | 0.0023 | 0.0023 | 0.1207 | 0.10 | 0.9084 | 1.01 | 7.28 | 388,440.70 | 1.71 | -9.03 | 1.98 | -10.92 | 94.30 | 93.52 | 1.88 | -10.49 | 4.52 | -0.582 | 0.1817 | -- | 59.53 | 61.65 | -312.95 | -- | 47.35 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 1.63bn | -- | -- | 25.88 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Neuren Pharmaceuticals Ltd | 237.63m | 157.08m | 2.49bn | -- | 15.95 | 12.09 | 15.85 | 10.48 | 1.22 | 1.22 | 1.84 | 1.61 | 1.63 | -- | 21.92 | -- | 107.87 | 49.80 | 127.30 | 55.37 | -- | -- | 66.10 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Telix Pharmaceuticals Ltd | 502.55m | 5.21m | 5.55bn | 234.00 | 1,175.51 | 36.11 | 464.27 | 11.04 | 0.0141 | 0.0141 | 1.55 | 0.46 | 1.54 | 14.59 | 9.65 | -- | 1.59 | -29.21 | 2.54 | -40.27 | 62.56 | 61.64 | 1.04 | -37.14 | 1.32 | 24.03 | 0.1049 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Polynovo Ltd's reporting currency: Australian Dollar AUD
11.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Jun 2024 | 22.60m | 3.27% |
| Vanguard Investments Australia Ltd.as of 30 Apr 2024 | 12.08m | 1.75% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Apr 2024 | 10.65m | 1.54% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 8.65m | 1.25% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 2024 | 7.13m | 1.03% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.45m | 0.93% |
| Netwealth Investments Ltd.as of 07 Aug 2023 | 4.28m | 0.62% |
| BetaShares Capital Ltd.as of 31 May 2024 | 3.68m | 0.53% |
| BlackRock Asset Management North Asia Ltd.as of 30 Apr 2024 | 2.13m | 0.31% |
| BlackRock Investment Management (Australia) Ltd.as of 06 Jun 2024 | 2.12m | 0.31% |
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
